Sana Biotechnology Past Earnings Performance
Past criteria checks 0/6
Sana Biotechnology's earnings have been declining at an average annual rate of -3%, while the Biotechs industry saw earnings growing at 22.1% annually.
Key information
-3.0%
Earnings growth rate
78.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -104.6% |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus
Dec 04Sana Biotechnology: The Story Becomes Murkier
Nov 19We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully
Nov 01Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline
Jul 14We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Jul 12Sana Biotechnology: Now In Overbought Territory
Mar 17Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)
Jan 11Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
Dec 30Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 14Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?
May 26We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Dec 19Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 03Sana Biotechnology A Buy For Potential Cancer Therapies
Jun 27Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
May 16Sana Biotechnology: Exciting Preclinical Science
Feb 12Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?
Oct 13Sana Biotechnology: Hypoimmune Cell Therapies
Jul 01Sana Biotechnology reports Q1 results
May 05Revenue & Expenses Breakdown
How Sana Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 0 | -306 | 68 | 229 |
30 Jun 24 | 0 | -245 | 73 | 223 |
31 Mar 24 | 0 | -309 | 73 | 281 |
31 Dec 23 | 0 | -283 | 73 | 254 |
30 Sep 23 | 0 | -276 | 67 | 246 |
30 Jun 23 | 0 | -362 | 63 | 284 |
31 Mar 23 | 0 | -320 | 61 | 248 |
31 Dec 22 | 0 | -269 | 58 | 204 |
30 Sep 22 | 0 | -300 | 56 | 232 |
30 Jun 22 | 0 | -298 | 54 | 232 |
31 Mar 22 | 0 | -207 | 53 | 135 |
31 Dec 21 | 0 | -356 | 50 | 275 |
30 Sep 21 | 0 | -358 | 47 | 266 |
30 Jun 21 | 0 | -327 | 41 | 230 |
31 Mar 21 | 0 | -433 | 34 | 336 |
31 Dec 20 | 0 | -285 | 28 | 232 |
30 Sep 20 | 0 | -215 | 25 | 174 |
31 Dec 19 | 0 | -131 | 22 | 102 |
Quality Earnings: SANA is currently unprofitable.
Growing Profit Margin: SANA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SANA is unprofitable, and losses have increased over the past 5 years at a rate of 3% per year.
Accelerating Growth: Unable to compare SANA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SANA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: SANA has a negative Return on Equity (-104.56%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 01:40 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sana Biotechnology, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Geoffrey Meacham | BofA Global Research |
Alec Stranahan | BofA Global Research |
Samantha Lynn Semenkow | Citigroup Inc |